Pds biotech unveils updated positive data from versatile-002 trial and additional trials evaluating versamune® hpv to treat head and neck cancers at the 2025 american society of clinical oncology (asco) annual meeting

Pds biotech announced the publication of three versamune® hpv abstracts that were presented during the head and neck cancer poster session at asco 2025.

PDS Ratings Summary

PDS Quant Ranking